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Abstract
Recent advances in genomics, proteomics, bioinformatics and systems biology have unraveled the
complex aberrant signaling networks in cancer. The knowledge accrued has dramatically increased
the opportunities for discovery of novel molecular targets for drug development. Major emphasis
is being laid on designing new therapeutic strategies targeting multiple signaling pathways for more
effective disease management. However, the translation of in vitro findings to patient management
often poses major challenges that limit their clinical efficacy. Here we will discuss how
understanding the dysregulated signaling networks can explain the pitfalls in translating the
laboratory findings from the bench-to-bedside and suggest novel approaches to overcome these
problems using head and neck cancer as a prototype. The five year survival rates of HNSCC
patients (about 50% at 5 years) have not improved significantly despite advancements in
multimodality therapy including surgery, radiation and chemotherapy. Molecular targeted therapies
with inhibitors of EGFR and VEGF either alone, or in combination with conventional treatments
have shown limited improved efficacy. The key deregulated signaling pathways in head and neck
squamous cell carcinoma (HNSCC) include EGFR, Ras, TGFβ, NFκB, Stat, Wnt/β-catenin and PI3-
K/AKT/mTOR. The aberrant activities of these interrelated signaling pathways contribute to
HNSCC development. In depth understanding of the cross-talks between these pathways and
networks will form the basis of developing novel strategies for targeting multiple molecular
components for more effective prevention and treatment of HNSCC.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common cancer accounting for over 500,000
new cases annually worldwide [1]. Despite improvement
in treatment strategies involving surgery, radiotherapy
(RT) and/or chemotherapy (CT), the prognosis of HNSCC
patients in advanced stages (III/IV) remains largely unsat-
isfactory owing to loco-regional recurrence [2,3]. Rand-
omized trials using CT (cisplatin/carboplatin alone, or in
combination with 5-Fluorouracil (5-FU), methotrexate or
paclitaxel and/or RT show increased loco-regional control
or survival and prevent subsequent metastasis by eradicat-
ing occult metastasis, though the dose limiting toxicities
or increased risk of cardiac failure in cancer patients limits
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their clinical utility [4-6]. Hence major thrust is being laid
on development of molecular targeted therapies for
HNSCCs.
Multiple epigenetic and genetic events, including the
aberrant expression and/or function of regulators of cell
cycle, growth and signaling, motility, apoptosis, angio-
genesis and microRNAs are implicated in pathogenesis of
HNSCCs and constitute plausible targets for therapy.
Advances in epigenomics, genomics, proteomics, bioin-
formatics and integration of this knowledge have pro-
vided holistic understanding of signaling pathways and
networks that regulate cellular functions, intra- and inter-
cellular communication, and tumor-host interactions.
The deregulation of signaling cascades including the
EGFR, Ras, NFκB, Stat, Wnt/β-catenin, TGF-β, and PI3-K/
AKT/mTOR pathways contributes to development of
HNSCC [7]. Here, we will discuss how this emerging
information on cross-talks between the different signaling
pathways and networks can help to understand the lim-
ited efficacy of mono-targeted therapies for HNSCC. In
turn, this knowledge can be harnessed for developing
novel multiple molecular-targeted strategies for HNSCC
treatment.
Molecular Targeted Therapies for HNSCC
Several molecular targeted therapies are currently being
developed for HNSCC. The signaling pathways deregu-
lated in HNSCC and the agents targeting key components
are schematically represented in Figure 1. The clinical effi-
Signaling pathways frequently deregulated in HNSCC, the molecular targets involved and their corresponding inhibitors as  potential anticancer agents Figure 1
Signaling pathways frequently deregulated in HNSCC, the molecular targets involved and their corresponding 
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cacies of these inhibitors targeting important pathways
regulated by epidermal growth factor receptor (EGFR),
vascular endothelial growth factor (VEGF) and AKT have
been reviewed [8-14]. Large amount of preclinical in vitro
and in vivo data have been obtained on the anti-prolifer-
ative properties of these inhibitors, both as single agents
and combined with CT/RT. The inclusion of these agents
in combined modality treatment regimes for early and/or
advanced stage HNSCC is likely to increase therapeutic
efficacy. Consequently, several targeted agents are under
clinical trials in HNSCC, with many phase I/II studies
already completed and some phase III studies in progress.
The limited efficacies of these trials and unexpected toxic-
ities in HNSCC patients have emphasized the difficulties
of translating in-vitro findings to clinics for disease man-
agement.
EGFR Inhibitors: Clinical Challenges
Activation of EGFR signaling is one of the mechanisms for
resistance to RT and/or CT in HNSCC, making it the most
plausible therapeutic target [15-17]. Upon ligand binding
(EGF or TGF α), EGFR forms a homodimer or het-
erodimer with other members of the Erb family (Her2/
neu, Erb3, Erb4) and activates downstream signaling cas-
cades-Ras/Raf/MAPK and the PI3K/Akt/mTOR pathways
(Figure 1). The activation of these signaling events is
responsible for regulating key tumorigenic processes such
as proliferation, inhibition of apoptosis, cell adhesion/
motility, growth and survival. Monoclonal antibodies
against the extra-cellular domain of EGFR, cetuximab, per-
tuzumab, panitumumab and trastuzumab, used as inhib-
itors in monotherapy have shown limited efficacy. In a
phase I/II trial, combination of cetuximab with 5-FU and
carboplatin/cisplatin showed increased survival with no
cumulative toxicity in recurrent HNSCC [18]. Cetuximab
acts as a tumor specific radiosensitizer [19,20]. EGFR inhi-
bition by cetuximab significantly reduced tumor repopu-
lation during fractionated RT in a xenografted human
model of SCC [21]. In contrast, trials with chemoradia-
tion (CRT) and cetuximab in HNSCC have shown adverse
events and withdrawal of the trial [22]. Humanized anti-
bodies- panitumumab and trastuzumab overcome the
dose dependent toxicity of cetuximab but are less immu-
nogenic and effective. Moreover, clinical trials of trastuzu-
mab for HNSCC have reported cardiomyopathy in
patients undergoing treatment. ErbB2 inhibition has been
shown to activate mitochondrial apoptosis by modulat-
ing the ratio of BCL-xL and -xS, resulting in cardiomyopa-
thy [23], but the exact mechanism of trastuzumab
induced cardiomyopathy is still unclear. Unlike mono-
clonal antibodies, tyrosine kinase inhibitors (TKIs) such
as gefitinib, erlotinib and lapatinib block the ATP pocket
of EGFR, thereby inhibiting phosphorylation and down-
stream signal transduction. A multicentric study showed
that erlotinib was well tolerated in pretreated HNSCCs
and prolonged disease free survival [24].
Although, EGFR overexpression is observed in more than
90% of HNSCCs, yet, only a subset of these tumors show
a clinically meaningful response to EGFR inhibition
[25,26]. Potential reasons for failure of response to EGFR
inhibitors include: constitutive activation of the Ras/Raf/
MAPK, STAT3 and PI3-K/AKT/mTOR signaling pathways
independent of EGFR by other stimuli such as hypoxia,
Ras activation or PTEN mutation and inhibition. The pres-
ence of EGFR variant III (EGFRvIII) in HNSCCs, is also
responsible for constitutive activation of downstream sig-
naling and resistance to EGFR inhibition by monoclonal
antibodies [27]. Acquired resistance to cetuximab is
accompanied by deregulation of EGFR internalization/
degradation and subsequent EGFR dependent activation
of HER3 [28]. EGFR inhibition by erlotinib/gefitinib is
overcome by epithelial-mesenchymal transition [29].
Recently, Hadad et al., [30] proposed a novel mechanism
for regulation of mesenchymal phenotype and resistance
to erlotinib in HNSCC cells by Delta-crystallin enhancer
binding factor 1. In addition, cross-talks between EGFR
and cell adhesion molecules, cytokine receptors, ion
channels and G protein coupled receptor (GPCR) lead to
EGFR activation [31]. GPCR-EGFR cross-talk may play a
role in development of HNSCC and account for limited
efficacy of EGFR inhibitors in HNSCC. The aforemen-
tioned mechanisms might also explain why most clinical
trials suggest no correlation between EGFR protein expres-
sion and response to EGFR inhibitors. Notably, favorable
outcome has been associated with skin toxicity or pres-
ence of shorter EGFR intron 1 cytosine-adenine repeats
[32]. As yet, there are no proven molecular predictors of
response to EGFR targeted antibodies [33]; search for
biomarkers should be extended to EGFR-activation status
and key components of downstream pathways. Tumor
signaling pathway components that work synergistically
with EGFR or compensate for the loss of EGFR-initiated
signaling are likely to be ideal targets for multi-targeted
therapy. Erb family-targeted and Src family-targeted
agents are in clinical development [34].
VEGF Inhibitors
Increased expression of VEGF and its receptors in
HNSCCs, underscores the importance of VEGF pathway
in angiogenesis and survival of tumor cells under hypoxic
conditions [35,36]. VEGF expression is regulated by
hypoxia-inducible factor -1α (HIF-1α) -dependent and
independent processes, both of which involve PI3-K and
AKT. Bevacizumab, a humanized VEGF monoclonal anti-
body, not only inhibits angiogenesis, but also facilitates
the increased delivery of chemotherapeutic agents by
decreasing microvascular permeability and decreasing
intratumor pressure. But, single-agent anti-angiogenic
drugs have not shown activity in unselected HNSCC
patients, with a response rate of less than 4%. On the
other hand, combinations of bevacizumab with erlotinib
showed a response rate of 14.6%. Studies of bevacizumabHead & Neck Oncology 2009, 1:6 http://www.headandneckoncology.org/content/1/1/6
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with CT (phase III Eastern Cooperative Oncology Group
[ECOG] trial) and in combination with CRT are currently
in progress [37]. However, HNSCCs show inter-tumoral
angiogenic heterogeneity; in-depth understanding of the
variability of angiogenic phenotype within a given
HNSCC is important for designing cytokine targeted anti-
angiogenic therapies.
Multikinase Inhibitors
Sorafenib, an oral multikinase inhibitor, targets serine/
threonine Raf-1 kinase and receptor tyrosine kinases
(RTKs)- VEGFR, PDGFR, KIT, and Flt3. Phase II trials in
recurrent or metastatic HNSCC patients showed that sor-
afenib was well tolerated with modest anticancer activity
comparable to monotherapy [38]. BIBF 1120, targets
VEGF, PDGF, FGF receptor and src family of tyrosine
kinases (Src, LcK, Lyn). Vandetanib (ZD6474), an inhibi-
tor of VEGFR, EGFR, and rearranged during transfection
(RET) tyrosine kinases is being tested in HNSCC as mon-
otherapy and also in combination with CT [39,40]. Dasat-
inib (BMS-354825) is a synthetic, small molecule
inhibitor of Src family kinases, also inhibits protein tyro-
sine kinases: bcr-abl, EphA2, PDGF-β [41]. But, a major
challenge in development of multikinase inhibitors is the
rapid evolution of mutant inhibitor resistant kinases,
therefore, appropriate multi-targeted inhibitors or combi-
nations need to be planned in advance of clinical applica-
tion.
PI3-K/AKT/mTOR pathway Inhibitors
Uncontrolled activation of the PI3-K/Akt/mTOR pathway
contributes to the development and progression of
HNSCC and is an important target to counteract resist-
ance to RT and/or CT [42]. PTEN deletions and 'hot-spot'
mutations of the PI3K gene have been shown to possess
transforming capacity in vitro and in vivo, hence restora-
tion of mutated or absent PTEN activity might be a target
for AKT inhibition. Protease inhibitors downregulate the
phosphorylation and expression of active PI3-K, that is
responsible for radioresistance in HNSCC. Akt activation
is a possible mechanism of resistance to EGFR inhibitors,
therefore, the combination of AKT inhibitors and anti-
EGFR agents may be useful in effective management of
HNSCC. The mammalian target of rapamycin, commonly
known as mTOR regulates cell growth, proliferation,
motility, survival, protein synthesis, and transcription.
Rapamycin derivatives such as everolimus, temserolimus
and deforolimus are potent inhibitors of mTOR and do
not share the problems of poor solubility and chemical
stability of rapamycin. A clinical trial using cisplatin and
everolimus (RAD-001) in HNSCC is in progress [43].
However, not all HNSCCs have activated PI3-K/Akt/
mTOR pathway, hence molecular signatures need to be
developed to define patients that may benefit from inhib-
itors of this pathway. Moreover, mTOR inhibition blocks
the natural negative feedback on insulin-like growth fac-
tor-1 receptor (IGF-1R) signaling impinging on PI3-K.
This results in increased PI3-K and Akt activation which
could potentially counteract the inhibition of mTOR.
Dual inhibition of both IGF-1R signaling or TKIs, and
mTOR may result in a superior anti-proliferative effect
over each single strategy in HNSCCs [44,45]. The major
limitation of mTOR inhibitors in clinical trials is their
dose limiting toxicity. Hence, natural products, such as
curcumin, which hit multiple cellular targets including
mTOR, in combination with mTOR inhibitors may reduce
the toxic side effects and augment the clinical efficacy.
Novel Biological Targeted Agents for HNSCC
Biological agents, pemetrexed and enzastaurin, an oral
protein kinase C beta (PKCbeta) inhibitor, are showing
considerable promise and no unexpected toxicities in
phase I trials in combination with cisplatin [46,47].
Aurora kinase A (AURKA) inhibitor and paclitaxel in com-
bination are also under investigation for HNSCC manage-
ment [48]. Among the new COX-2 inhibitors, Salvianolic
acid B (Sal-B) has shown promise for HNSCC prevention
and treatment [49]. Geldanamycin analogues have dem-
onstrated potent inhibition of Hsp90 demonstrating sig-
nificant anti-tumor activity in both cell culture and
animal studies. Bortezomib inhibits activation of NFκB
and sensitizes these cells to chemotherapy, radiation, or
immunotherapy without added toxicities [50-53]. His-
tone deacetylases (HDACs) are enzymes that regulate the
acetylation of histone proteins and non-histone proteins
including p53, p21, NFκB. Altered expressions of HDACs
have been reported in several human malignancies
including head and neck cancer. Inhibitors of HDAC such
as suberoylanilide hydroxamic acid have been shown to
induce growth arrest, differentiation and promote apop-
tosis of HNSCC cell lines [54]. HDAC inhibitors target
NFκB and also increase radiosensitivity and thus may be
tried in future trials.
Challenges in Molecular Targeted Therapies for HNSCC
The complexity of the aberrant signaling in HNSCC (Fig-
ure 1 &2) explains why interfering with only single steps
in these pathways have not shown marked clinical
response in HNSCC patients. HNSCC cells have the abil-
ity to exploit diverse signaling pathways for growth advan-
tage, cell survival and evasion of apoptosis. In fact, some
of these processes may even be facilitated by the use of
selective targeted agents and warrant interference at differ-
ent stages for reducing the tumor burden effectively. Fur-
ther, different etiological factors and risk habits can result
in distinct genetic and epigenetic alterations, which may
trigger different signaling pathways that impact develop-
ment and progression of HNSCCs. A proof of principle is
the constitutive activation of Ras/Raf/MAPK pathway due
to Ras mutations in the areca quid chewing oral cancers,Head & Neck Oncology 2009, 1:6 http://www.headandneckoncology.org/content/1/1/6
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while in cancers associated with chronic tobacco exposure
this pathway is likely to be activated downstream from
EGFR activation. Another evidence of multiple aberrant
pathways is the altered NFκB function leading to activa-
tion of STAT3 by an autocrine or paracrine mechanism
initiated by IL-6 release, independent from EGFR. In addi-
tion, de novo/acquired chemoresistance comprises a sig-
nificant problem in management of HNSCCs. The
emerging data suggests Cancer Stem Cells (CSCs) may be
responsible for acquired resistance to CT/RT in HNSCCs.
Cancer stem cells is a subpopulation of cells that can self-
renew and produce differentiated cells that form the bulk
of the tumor [55]. It is proposed that the current HNSCC
treatment regimens selectively kills the differentiated can-
cer cells producing tumor regression, but do not eliminate
the cancer stem cells. Understanding the molecular signa-
tures of HNSCC stem cells will define new targets for
designing of novel therapeutic strategies.
Little attention has been paid to understanding the effect
of human papillomavirus (HPV) on therapeutic response
to targeted agents in HNSCC. It is being increasingly rec-
ognized that the molecular pathogenesis of HPV infected
oropharyngeal SCC exhibits marked geographical varia-
tion [56] and is different from tobacco and alcohol asso-
ciated HNSCC [7,13,57], so how can these biologically
different tumors show the same response to targeted
agents? In fact, HPV associated HNSCC show better prog-
Network analysis using Ingenuity pathway analysis (IPA) software Figure 2
Network analysis using Ingenuity pathway analysis (IPA) software. This figure depicts the merged networks of pro-
teins/molecules targeted for novel therapies in HNSCCs. These proteins/molecules form a complex network responsible for 
survival and proliferation of cancer cells. Therefore, targeting this complex network with single agents or monotherapy is often 
a failure as blocking a single pathway triggers alternate signaling cascades to activate downstream targets for survival. The bold 
lines show a direct association among different proteins/molecules while the dashed lines represent indirect regulation or asso-
ciation among these proteins. As shown, all members of Erb family are directly associated; hence dowregulating/blocking one of 
the members does not block downstream signaling via Ras/Raf/Mapk and PI3K/Akt/mTOR pathway completely. Also, as shown 
in figure, these pathways are also being regulated by Insulin, TGF-β and KDR (VEGFR), PDGFR and HIF1α.Head & Neck Oncology 2009, 1:6 http://www.headandneckoncology.org/content/1/1/6
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nosis than HPV negative tumors, though the molecular
basis of improved prognosis is not clearly understood.
Nevertheless, in future trials, evaluation of HPV status of
HNSCC patients is likely to provide better insight into the
outcome of clinical response to targeted agents.
Future Strategies
The development of new biological agents should focus
on inhibitors that are likely to hit multiple targets. Alter-
natively, combination of different agents that target dis-
tinct specific pathways is likely to inhibit the escape of
tumor cells by alternate mechanisms leading to more
effective disease control. But, the success of future clinical
trials will depend upon (i) patient population and (ii)
study design for assessment of response to therapy. Fur-
ther, to evaluate the efficacy of these biological agents
there is urgent need to identify novel biomarkers that can
be used to accurately assess and individualize therapy.
Patient population selection
Phase II trials are often conducted on patients having
advanced loco-regional disease or recurrent/metastatic
HNSCC and have several limitations: (i) most patients
have received RT/CT/CRT for the primary tumors, often
develop multifactorial resistance and are less likely to
respond to new agents effectively. This is best exemplified
by the outcome of trials with cetuximab. In advanced
HNSCC patients' refractory to platinum, cetuximab
showed a response rate of 13%, while the response rate
increased to 20% in patients who were stable on platinum
therapy [10]. Hence testing of new agents as first line ther-
apy is likely to show better clinical response than in recur-
rent/metastatic HNSCC patients; (ii) cumulative
resistance observed in recurrent/metastatic HNSCC
patients limits the generalization of clinical response to
patients with early disease for target validation; (iii) feasi-
bility of conducting translational research is hampered by
the ethical constraints in obtaining tumor biopsies. A par-
adigm shift in design of phase II trials is proposed that
enables evaluation of new compounds in pre-operative
window setting. The collection of biopsies before treat-
ment at the time of diagnosis, and after treatment, either
at the time of surgery or before loco-regional therapy will
permit assessment of predictive molecular markers and
may help in identifying subgroups of patients most likely
to respond to therapy (or develop primary resistance). In
addition, these paired tumor specimens are likely to pro-
vide insights into the pharmacodynamic effects of novel
agents, and their mechanism of action. Establishment of a
data base documenting the specificities of the inhibitors
and observed toxicities in Phase I and Phase II studies
would provide a valuable resource for understanding
whether there are particular cellular targets whose inhibi-
tion should be avoided.
Molecular markers for assessment of biological response
Evaluation of clinical response dependent on progression-
based endpoints is likely to provide more realistic assess-
ments of the anti-tumor activity of biological agents. Spe-
cific molecular markers may give a more objective
evaluation of clinical response. To cite an example – phar-
macodynamic tissue studies conducted on a phase I/II
trial of erlotinib and cisplatin in patients with recurrent or
metastatic HNSCC showed that high EGFR gene copy in
tumor specimens may predict which patients are likely to
respond to erlotinib, and decreased p-EGFR level in skin
biopsies during therapy may represent a potential surro-
gate marker for improved clinical outcome. Multidimen-
sional scaling (MDS) was shown to represent a novel way
to evaluate these relationships between molecular mark-
ers and clinical outcome [58]. Molecular imaging or
dynamic control enhanced CT/MRI may be used for meas-
urement of intra-tumoral blood flow perfusion parame-
ters to evaluate the clinical efficacy of anti-angiogenic
agents.
There is a need for more predictive tumor models and bet-
ter ways to monitor target inhibition in humans in a min-
imally invasive manner. As cell culture and animal
models are severely limited in mimicking the develop-
ment of human HNSCC, there is an urgent need to
develop minimally invasive methods to discover and
monitor biomarkers for evaluation of HNSCC in humans.
New imaging modalities in conjunction with proteomic
technologies may be investigated to monitor changes in
signaling proteins and metabolites. Early detection tech-
nologies may allow us to diagnose and exterminate
tumors prior to acquisition of survival capabilities that
empower them with resistance to therapy.
In conclusion, in depth understanding of how the com-
plex cellular signaling cascades and networks are repro-
grammed in HNSCC and in the presence of mono-
targeting inhibitors is vital to rational designing of combi-
nations of inhibitors. Innovative trial designs and appro-
priate patient selection are critical for the success of new
trials to translate molecular targeted therapies from the
bench to the clinics.
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